menu
    • menu

    Company profile for Thryv Therapeutics

    NEW Drugs in Dev: 3
    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Sigma-Aldrich empowers scientific discovery with top-quality solutions to accelerate research, innovation, and better health worldwide.

    Virtual Booth

    Contact Supplier

    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    Virtual Booth

    Contact Supplier

    TransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Thryv Therapeutics Inc., previously called LQT Therapeutics Inc. is a privately owned company based in Montreal, Quebec, Canada. They have been pioneering a precision medicine approach to treat Long QT Syndrome via SGK1 inhibition since 2019 and have since evolved their portfolio to include the treatment of resistant and rare cancers. The development of SGK1 inhibitors represents a novel approach to target treatment-resistant ...
    Thryv Therapeutics Inc., previously called LQT Therapeutics Inc. is a privately owned company based in Montreal, Quebec, Canada. They have been pioneering a precision medicine approach to treat Long QT Syndrome via SGK1 inhibition since 2019 and have since evolved their portfolio to include the treatment of resistant and rare cancers. The development of SGK1 inhibitors represents a novel approach to target treatment-resistant cancers, and complement existing therapies.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Thryv TherapeuticsCanada Flag
    Country
    Country
    Canada
    Address
    Address
    999, boulevard De Maisonneuve Ouest , Suite 1250, Montréal, Québec H3A 3L4
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://thryvtrx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/thryv-therapeutics-inc/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    IMCAS Asia

    IMCAS Asia

    Not Confirmed

    envelop Contact Supplier

    IMCAS Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Thryv Therapeutics at UBS, RBC & Jefferies Conferences
    Thryv Therapeutics at UBS, RBC & Jefferies Conferences

    12 May 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/thryv-therapeutics-to-participate-in-ubs-rbc-capital-markets-and-jefferies-healthcare-conferences-302769163.html

    PR NEWSWIRE
    12 May 2026
    Share Share
    Thryv Therapeutics Begins Wave II Dosing, Gets FDA Fast Track
    Thryv Therapeutics Begins Wave II Dosing, Gets FDA Fast Track

    22 Apr 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/thryv-therapeutics-commences-patient-dosing-in-wave-ii-clinical-study-for-long-qt-syndrome-and-receives-fda-fast-track-designation-for-thrv-1268-302749402.html

    PR NEWSWIRE
    22 Apr 2026
    Share Share
    Thryv Therapeutics Initiates Phase 2/3 Study For Long QT Syndrome
    Thryv Therapeutics Initiates Phase 2/3 Study For Long QT Syndrome

    13 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/thryv-therapeutics-launches-pivotal-wave-ii-phase-23-study-in-long-qt-syndrome-type-2-302659854.html

    PR NEWSWIRE
    13 Jan 2026
    Share Share
    Thryv Therapeutics Reports Positive Phase 1 Results
    Thryv Therapeutics Reports Positive Phase 1 Results

    17 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/thryv-therapeutics-announces-positive-phase-1-results-of-thrv-1268-in-obese-participants-302644754.html

    PR NEWSWIRE
    17 Dec 2025
    Share Share
    Thryv Therapeutics Appoints Matt Killeen Chief Business Officer
    Thryv Therapeutics Appoints Matt Killeen Chief Business Officer

    02 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/thryv-therapeutics-strengthens-senior-leadership-team-with-appointment-of-matt-killeen-phd-as-chief-business-officer-302629545.html

    PR NEWSWIRE
    02 Dec 2025
    Share Share
    Amy Rudolph Joins Thryv Board, Advancing Heart Failure Portfolio
    Amy Rudolph Joins Thryv Board, Advancing Heart Failure Portfolio

    19 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/amy-rudolph-phd-joins-thryv-therapeutics-board-of-directors-to-support-portfolio-progression-into-heart-failure-302620430.html

    PR NEWSWIRE
    19 Nov 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search